Nebulizer developer Respira Technologies, which recently announced the appointment of Brian Quigley as CEO, has changed its name to "Qnovia," the company said. No reason for the name change was announced, but the previous name was similar to that of Respira Therapeutics, which is developing a vardenafil DPI for the treatment of pulmonary arterial hypertension … [Read more...] about Respira Technologies changes its name to Qnovia
Business
Iliad Biotechnology raises $42.8 million for Phase 2b study of BPZE1 intranasal pertussis vaccine
Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company's BPZE1 intranasal pertussis vaccine as well as other development and manufacturing activities. The company said that the new funding brings the total for development of BPZE1 to more than $100 … [Read more...] about Iliad Biotechnology raises $42.8 million for Phase 2b study of BPZE1 intranasal pertussis vaccine
Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso
The United States District Court for the District of Delaware has ruled that Liquidia's Yutrepia treprostinil DPI would infringe claims contained in US patents 9,593,066 and 10,716,793, which cover United Therapeutics' Tyvaso inhaled treprostinil; however, the judge found that the claims in the '066 patent that would be infringed are invalid and the sole valid claim … [Read more...] about Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso
Orexo gets European patent covering OX640 intranasal dry powder adrenaline
The European Patent Office (EPO) has granted Orexo a patent (EP 3962455B1) covering the company's OX640 intranasal dry powder adrenaline, which is in Phase 1 development for the emergency treatment of anaphylaxis. According to the company, the European patent will protect OX640 until May 2041. OX640 intranasal adrenaline is based on the same technology as the … [Read more...] about Orexo gets European patent covering OX640 intranasal dry powder adrenaline
Hikma launches Ryaltris nasal spray in the US
Hikma Pharmaceuticals has launched Ryaltris olopatadine / mometasone nasal spray in the US, the company said. Hikma acquired US rights to Ryaltris in February 2020, and the FDA approved Glenmark's NDA for the nasal spray for the treatment of seasonal allergic rhinitis in January 2022. The company's US catalog includes several other nasal sprays, including … [Read more...] about Hikma launches Ryaltris nasal spray in the US
Wockhardt subsidiary Morton Grove Pharmaceuticals ordered to stop manufacturing
A US District Court has ordered Wockhardt subsidiary Morton Grove Pharmaceuticals "to stop manufacturing and distributing drugs alleged to be adulterated." The Morton Grove facility manufactured fluticasone propionate nasal sprays in addition to other products. The company has signed a consent decree agreeing to cease production, to destroy already manufactured drugs, … [Read more...] about Wockhardt subsidiary Morton Grove Pharmaceuticals ordered to stop manufacturing
Nob Hill names Noel Greenberger as CEO, gets $1.7 million grant for development of a nebulized dry powder antifungal
Dry powder nebulizer developer Nob Hill Therapeutics announced the appointment of Noel Greenberger as its new CEO, replacing interim CEO Yun Li as of September 1, and said that it has received a Department of Health and Human Services (HHS) Small Business Innovation Research (SBIR) Phase 2 grant of up to $1.73 million for development of a dry powder antifungal … [Read more...] about Nob Hill names Noel Greenberger as CEO, gets $1.7 million grant for development of a nebulized dry powder antifungal
SaNOtize raises $24 million for development of NONS nitric oxide nasal spray
SaNOtize announced that it has closed a $24 million Series B funding round led by Horizons Ventures and OurCrowd with proceeds to go towards continued development of the company’s NONS nitric oxide nasal spray. The company initiated a Phase 3 trial of NONS for the treatment of COVID-19 in June 2021 and announced positive results from that study in July 2022. In August … [Read more...] about SaNOtize raises $24 million for development of NONS nitric oxide nasal spray
Lee’s acquires global rights to Windtree’s Aerosurf aerosolized KL4 surfactant
Windtree Therapeutics said that it has signed a deal with Lee’s Pharmaceutical and its subsidiary Zhaoke Pharmaceutical giving Lee's global rights to develop and commercialize Windtree surfactants for any potential indications, including Aerosurf aerosolized KL4 surfactant for the treatment of premature infants with respiratory distress syndrome. According to … [Read more...] about Lee’s acquires global rights to Windtree’s Aerosurf aerosolized KL4 surfactant
NIH announces availability of licensing for IP related to nebulized thrombin inhibitors for the treatment of SARS-CoV-2-induced lung fibrosis
The US National Institutes of Health (NIH) has published a notice in the Federal Register regarding the availability of intellectual property related to the use of inhaled thrombin inhibitors for the treatment of lung fibrosis caused by SARS-CoV-2 infection. The notice says that the technology "is available for licensing to achieve expeditious commercialization of … [Read more...] about NIH announces availability of licensing for IP related to nebulized thrombin inhibitors for the treatment of SARS-CoV-2-induced lung fibrosis